Eindhoven Xeltis Martijn Cox

Xeltis today announced the completion of an oversubscribed €45 Million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurma Partners and VI Partners) also participated in the financing.

This is the largest investment round for a private medical device company in Europe in 2017, Xeltis says. The Series C financing will support continuation of clinical activities and acceleration of product and market development for the company’s novel aortic and pulmonary valve programs.

“This robust financing provides us with the resources necessary to catapult our strategy forward – supporting a quick expansion of our aortic and pulmonary valve programs and strengthening our quest to redefine heart valve replacement therapy,” said Xeltis Chief Executive Officer (CEO) Laurent Grandidier.

Support us!

Innovation Origins is an independent news platform that has an unconventional revenue model. We are sponsored by companies that support our mission: to spread the story of innovation. Read more.

At Innovation Origins, you can always read our articles for free. We want to keep it that way. Have you enjoyed our articles so much that you want support our mission? Then use the button below:

Doneer

Personal Info

About the author

Author profile picture Bart Brouwers is co-founder and co-owner of Media52 BV, the publisher of innovationorigins.com.